Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health — ICR Conference 2021
25 slides from Vireo Growth's conference presentation, Jan 12, 2021
Slide 1: ICR Conference Presentation
“ We are building the cannabis company of the future by bringing the best of science, medicine and ICR Conference Presentation engineering to the cannabis industry. January 12, 2021 CNSX: VREO OTCQX: VREOF Kyle Kingsley, M.D. Founder & CEO
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-lo
Slide 3: Key Investment Highlights
Key Investment Highlights • Scientific expertise differentiates as a core competency within the industry. • Focus on intellectual property development is driving compelling long-term opportunities. • Impressive track record of winning licenses through merit-based awards and minimal investment. • Ass
Slide 4: Vireo At A Glance: Key Statistics
Vireo At A Glance: Key Statistics 400+ 29 Employees Dispensary Licenses 8Manufacturing Licenses Research Partnerships 8 $30M 8 FY19 Revenue States (1) 12 Patents-Pending (1) Including Puerto Rico. 4
Slide 5: Our Strategy to Maximize Stakeholder Value
Our Strategy to Maximize Stakeholder Value 01 Optimize the MSO for Cash Flow • Scale Core Markets to Meet Increasing Demand 03 Create a Best-in-Class Consumer Experience • Maintain Lean Operations • Delight All Demographics with Welcoming Retail • Disciplined Approach to Capital Allocation Dispensar
Slide 6: Optimize the MSO for Cash Flow: Our MSO Operating Footprint
Optimize the MSO for Cash Flow: A unique portfolio of assets widely regarded as one Our MSO Operating Footprint of the most attractive in the U.S. cannabis industry MN MA NY NV OH MD AZ NM Current Footprint Subject to pending transactions 6 Puerto Rico
Slide 7: Optimize the MSO for Cash Flow: Our MSO Operating Footprint
Optimize the MSO for Cash Flow: A unique portfolio of assets widely regarded as one Our MSO Operating Footprint of the most attractive in the U.S. cannabis industry Core markets expected to transition to adult-use within the next 6-24 months Non-core market candidates for development or divestiture
Slide 8: Lead with Science in Everything We Do: Intellectual Property Portfolio
Lead with Science in Everything We Do: Intellectual property creates monetizable partnership Vireo’s Intellectual Property Portfolio opportunities; preserves long-term product margins Short-Term Monetization (potential revenue generation in the next 12-24 months) Cannabis Moist Snuff Composition Mul
Slide 9: Lead with Science: Our Physician Leadership
Lead with Science in Unmatched medical expertise within Everything We Do: the cannabis industry Our Physician Leadership CHIEF EXECUTIVE OFFICER CHIEF MEDICAL OFFICER DIRECTOR OF MEDICAL • Board-certified emergency • Board-certified family physician EDUCATION medicine physician and successful with o
Slide 10: Our Healthcare and Medical Research Partnerships
Lead with Science in Everything We Do: Our Healthcare and Medical Vireo’s medical research partnerships are helping secure cannabis’ future as a viable healthcare alternative Research Partnerships Exclusive agreement to study the Randomized trial of medical Study to evaluate cannabis use Study to ev
Slide 11: Year-to-Date Performance: Key Metrics
Year-to-Date Performance: Key Metrics Three Months Ended Nine Months Ended September 30, September 30, US $ in millions 2020 2019 Variance 2020 2019 Variance Total Revenue, Including Disc. Ops $13.4 $8.0 67.6% $36.8 $21.0 75.6% Reported Results Revenue1 $11.9 $7.1 67.4% $33.3 $19.1 74.5% Gross Profi
Slide 12: State Performance & Development Update
State Performance & Development Update For the Nine Months Ended • As of September 30, 2020, the Company had cash on September 30, 2020 2019 $ Change % Change hand of $16.3 million, which does not include approximately $16.0 million in expected cash proceeds Retail: resulting from the redemption of
Slide 13: Best-In-Class Consumer Experience: Our Retail Dispensaries
Best-In-Class Consumer Green Goods™ retail dispensaries are currently being introduced across Vireo’s geographic footprint Experience: Our Retail Dispensaries Customer experience is amplified by e-commerce and home delivery in select markets. Green Goods™ Retail Concept Caters to Complete Cannabis C
Slide 14: Augment Retail with Home Delivery & E-Commerce
Best-In-Class Consumer Experience: Augment Retail with Home Delivery & E-Commerce: Our Medical Marijuana Products Delivered in 3 Easy Steps 1 2 3 Order Online Track Your Delivery Accept Delivery Select from a wide We’ll keep you We’ll notify you a few array of medical updated on the minutes before y
Slide 15: Build Meaningful Brands on Products Backed by Science
Build Meaningful Brands on Products Backed by Science Pharmaceutical-grade Products Innovative soft gels that delivers Premium-grade cannabis Geared Toward Patients consistent and precise doses for handpicked, hand-packaged, and A micro dose of cannabis in a the desired effect. cured for extended ti
Slide 16: Pursue Opportunistic Growth
Pursue Opportunistic Growth Positioned to drive upside growth opportunities through these categories: Merit-Based License Cost-Effective Strategic Partnerships Awards M&A Activity • Vireo’s existing footprint was We will pursue M&A opportunities • Our IP portfolio and scientific primarily built thro
Slide 17: Appendix
VY | C eC e) APPENDIX f a
Slide 18: Corporate Timeline
Corporate Timeline 2014 2015 2017 2018 2019 December June April June January Awarded 1 of 2 Awarded 1 of only 5 vertically- Launched NYC & Long Island’s Raised $17MM in a Series Acquisition of RI License vertically integrated integrated licences in NY first-ever medical marijuana D Round licenses in
Slide 19: Executive Management Team
Executive Management Team Kyle Kingsley, M.D. – Chief Executive Officer Amber Shimpa – Chief Administrative Officer Dr. Kingsley is a board-certified emergency medicine physician, entrepreneur, and Amber serves as Chief Administrative Officer and has been with Vireo Health inventor. Dr. Kingsley has
Slide 20: Board of Directors
Board of Directors Kyle Kingsley, M.D. – Chief Executive Officer Amber Shimpa – Chief Administrative Officer Dr. Kingsley is a board-certified emergency medicine physician, entrepreneur, and Amber serves as Chief Administrative Officer and has been with Vireo Health inventor. Dr. Kingsley has a stro
Slide 21: Consolidated Statements of Loss and Comprehensive Loss
Vireo Health, Inc. Consolidated Statements of Loss and Consolidated Statements of Loss and Comprehensive Loss Three Month Three Month Comprehensive Loss Period Ended Period Ended For the Three Months Ended September 30, 2020 and 2019 September 30, September 30, (Unaudited - Expressed in United State
Slide 22: Consolidated Statements of Financial Position
Vireo Health, Inc. Consolidated Statements of Financial Position Consolidated Statements of Financial Position As at September 30, 2020 and December 31, 2019 September 30, December 31, (Unaudited - Expressed in United States Dollars) 2020 2019 ASSETS Current Assets Cash $ 16,281,768 $ 7,641,673 Rest
Slide 23: Consolidated Statements of Cash Flows
Vireo Health, Inc. Consolidated Statements of Cash Flows Consolidated Statements of Cash Flows Nine Months Ended Nine Months Ended For the Nine Months Ended September 30, 2020 and 2019 September 30, September 30, (Unaudited - Expressed in United States Dollars) 2020 2019 Cash Flows from Operating Ac
Slide 24: Reconciliation of IFRS to Non-IFRS Financial Measures
Reconciliation of IFRS to Non-IFRS Financial Measures Three Months Ended September 30, 2020 2019 Net income (loss) $ 122,252 $ (14,565,506) Interest expense, net 1,356,834 871,781 Accretion expense 19,669 72,976 Income taxes 6,064,900 (3,506,000) Depreciation 355,450 515,486 Amortization 153,357 727
Slide 25: Contact Us
Contact Us investor@vireohealth.com www.vireohealth.com